ESTRO 2025 - Abstract Book

S2311

Interdisciplinary – Health economics & health services research

ESTRO 2025

Material/Methods: Surviving adult patients and caregivers of pediatric survivors from the initial cohort were re-contacted via postal correspondence and invited to complete the validated FACIT-COST questionnaire, to evaluate financial toxicity. (2) This questionnaire was already completed by participants directly after PT treatment. Furthermore, a demographic questionnaire to capture updated information on household income and employment status and other relevant variables was sent out. Adults additionally received the EORTC-QLQ-C30 questionnaire to evaluate current health related quality of life.(3) Results: Of the 146 participants included in the first study, 122 (83.6%) were alive at the beginning of this follow-up study. Among the 118 eligible participants contacted, 79 agreed to participate, corresponding to a response rate of 67.0% (CONSORT diagram, figure1). Mean age of the adult patients and children was 48.6±15.6 and 8.7±4.9 years, respectively. Most study participants came from urban areas (adults, 67.3%; children, 55.6%). Mean follow-up time was 3.77±0.62 years. The median FACIT-COST score for the whole cohort at follow-up was 31.00 (IQR [22.00, 38.00]), reflecting a marginal improvement compared to 30.00 (IQR [21.50, 37.20]) immediately after PT treatment (better financial well-being) (figure2). For the adult and pediatric subgroups, the corresponding scores were 29.00/30.95 and 34.00/27.00, respectively. There was a significant correlation between the EORTC-QLQ-C30 questionnaire item on financial difficulties and the FACIT-COST score at follow-up among the adult cohort (Spearman’s rho = -0.653, p < 0.001).